AKT1 and cancer: As the PI3K/AKT and MAPK pathways are major survival and proliferative signalling pathways, respectively, and are commonly constitutively activated in cancer, simultaneous inhibition of these pathways by combined MEK and PI3K inhibition may be required for optimal antitumour activity (Kohno and Pouyssegur, 2006).